Clinical trials are also evaluating the potential of humanized monoclonal antibodies against PD-1 (nivolumab and pembrolizumab) and against CTLA-4 (tremelimumab and ipilimumab) for the treatment of HCC patients [121]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.